Cost analysis of pharmaceutical care provided to HIV-infected patients: An ambispective controlled study

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Carnevale, Renata Cavalcanti ^a   De Godoi Rezende Costa Molino, Caroline ^a   Visacri, Marília Berlofa ^a   Mazzola, Priscila Gava ^a   Moriel, Patricia ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

HIV infected patients; Pharmaceutical care; Pharmacoeconomics

Indexed keywords

EFAVIRENZ; ILLICIT DRUG; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AFRICAN; ALCOHOL ABUSE; ARTICLE; BLACK PERSON; BRAZIL; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; ETHNICITY; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; INVESTMENT; LABORATORY TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TOXOPLASMOSIS; TREATMENT DURATION; VIRUS LOAD; ECONOMICS; MIDDLE AGED; PHARMACY; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; BRAZIL; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84924260896     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-014-0074-5     Document Type: Article

References (39)

1. Brazil, Ministry of Health, Secretária de Vigilância em Saúde, Programa Nacional de DST e Aids: Recomendações para Terapia Anti-retroviral em Adultos Infectados pelo HIV 2008 [http://www.ensp.fiocruz.br/portal-ensp/judicializacao/pdfs/491.pdf]
2. Dipiro J, Talbert R, Yees G, Matzke G, Wells B, Posey L: Pharmacotherapy: A Pathophysiologic Approach. 6th edition. Rio de Janeiro: Mcgraw Hill Companie; 2007.
3. Okie S: Fighting HIV-Lessons from Brazil. N Engl J Med 2006, 354:1977-1981.
4. Ma A, Chen DM, Chau FM, Saberi P: Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 2010, 22:1189-1194.
5. Carcelero E, Tuset M, Martin M, De Lazzari E, Codina C, Miró J, Gatell J: Evaluation of antiretroviral-related errors and interventions by the clinical pharmacist in hospitalized HIV-infected patients. HIV Med 2011, 12:494-499.
6. Hirsch J, Gonzales M, Rosenquist A, Miller T, Gilmer T, Best B: Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm 2011, 17:213-223.
7. March K, Mak MM, Louie SG: Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic. Am J Heal Syst Pharm 2007, 64:2574-2578.
8. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, Tyrer M, Chaloner C, Wilson D, Loveday C, Johnson MA, Phillips AN: Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001, 15:185-194.
9. Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM: The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence 2012, 6:297-322.
10. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL: Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003, 23:113-132.
11. Bozek PS, Perdue BE, Bar-Din M, Weidle PJ: Effect of pharmacist interventions on medication use and cost in hospitalized patients with or without HIV infection. Am J Health Syst Pharm 1998, 55:1151-1155.
12. Engles-Horton LL, Skowronski C, Mostashari F, Altice FL: Clinical guidelines and pharmacist intervention program for HIV-infected patients requiring granulocyte colony-stimulating factor therapy. Pharmacotherapy 1999, 19:356-362.
13. Horberg M, Hurley L, Silverberg M, Kinsman C, Quesenberry C: Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 44:531-539.
14. De Rijdt T, Willems L, Simoens S: Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm 2008, 65:1161-1172.
15. Areda CA, Bonizio RC, Freitas O: Pharmacoeconomy : an indispensable tool for the rationalization of health costs. Braz J Pharm Sci 2011, 47:231-240.
16. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M: Risk of cardiovascular disease from antiretroviral therapy for HIV : a systematic review. PLoS One 2013, 8:e59551.
17. Dube MP: Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1467-1475.
18. Friis-Møller N, Sabin CA, Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group, Weber R, D'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
19. Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, Weintrob A, Barthel RV, Fraser S, Infectious Disease Clinical Research Program HIV Working Group, Agan BK: Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 2010, 5:e10106.
20. Strand LM, Cipolle RJ, Morley PC: Documenting the clinical pharmacists activities: back to basics. Drug Intell Clin Pharm 1988, 22:63-67.
21. University of Minnesota College of Pharmacy. Pharmacy workup notes [http://www.pharmacy.umn.edu/medmanagenotes/]
22. Molino CGRC, Carnevale RC, Rodrigues AT, Visacri MB, Moriel P, Mazzola PG: Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection. Ther Clin Risk Manag 2014, 10:631-639.
23. DATASUS: SGTAP - Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS [http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp].
24. Ruiz I, Olry A, López MA, Prada JL, Causse M: Prospective, randomized, two-arm controlled study to evaluate two interventions to improve adherence to antiretroviral therapy in Spain. Enferm Infecc Microbiol Clin 2010, 28:409-415.
25. Martin S, Wolters P, Calabrese S, Toledo-Tamula MA, Wood LV, Roby G, Elliott-DeSorbo DK: The antiretroviral regimen complexity index. A novel method of quantifying regimen complexity. J Acquir Immune Defic Syndr 2007, 45:535-544.
26. Mok S, Minson Q: Drug-related problems in hospitalized patients with HIV infection. Am J Health Syst Pharm 2008, 65:55-59.
27. Rastegar D, Knight A, Monolakis J: Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis 2006, 43:933-938.
28. Pastakia S, Corbett A, Raasch R, Napravnik S, Correll T: Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. Ann Pharmacother 2008, 42:491-497.
29. Misson J, Clark W, Kendall M: Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection. J Clin Pharm Ther 1997, 22:109-117.
30. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353:487-497.
31. Langford SE, Ananworanich J, Cooper DA: Predictors of disease progression in HIV infection : a review. Aids Res Ther 2007, 4:1-14.
32. Brazil, Ministry of Health, Secretaria de Vigilancia em Saúde, Departamento de DST Aids e Hepatites Virais: Boletim Epidemiológico - AIDS e DST. 2012 [http://www.aids.gov.br/sites/default/files/anexos/publicacao/2011/50652/boletim-aids-2011-final-m-pdf-26659.pdf]
33. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG: Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000, 12:399-404.
34. Shen J, Sun Q, Zhou X, Wei Y, Qi Y, Zhu J, Yan T: Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital. Int J Clin Pharm 2011, 33(6):929-933.
35. Yen Y-H, Chen H-Y, Wuan-Jin L, Lin Y-M, Shen WC, Cheng K-J: Clinical and economic impact of a pharmacist-managed i.v.-to-p.o. conversion service for levofloxacin in Taiwan. Int J Clin Pharmacol Ther 2012, 50:136-141.
36. Brennan TA, Dollear TJ, Hu M, Matlin OS, Shrank WH, Choudhry NK, Grambley W: An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. Health Aff (Millwood) 2012, 31:120-129.
37. Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE: Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm 2002, 59:2070-2077.
38. Janknegt R, Meer JWM van der: Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994, 33:169-177.
39. Brazilian Health Surveillance Agency (ANVISA): Preços máximos de medicamentos por princípio ativo para compras públicas - monodrogas/preços fábrica (PF) e preço máximo de venda ao governo (PMVG) [http://portal.anvisa.gov.br/wps/wcm/connect/de29e2004 baf729293c5dbbc0f9d5b29/LISTA-CONFORMIDADE-GOV-2012-06-19.pdf? MOD=AJPERES. Accessed July 12, 2014].